Enveric Biosciences Inc (ENVB) Institutional Holdings & 13F Data (Q2 2026)

ENVB ranks #7974 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ENVB is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

24 institutions disclose a position in ENVB, but none treat it as a major bet — even Sio Capital Management, LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

UBS Group AG has trimmed its ENVB position for two straight quarters, cutting it by $10.2K while still holding $277.0.

ENVB reported a net loss of $8.7M over the trailing twelve months.

• Not yet profitable — net loss of $8.7M over the trailing twelve months
• Net income improved year over year, from -$9.9M to -$8.7M
• Operating cash flow was negative, using $8.1M in cash
• Current ratio of 5.38x — enough short-term assets to cover short-term liabilities
• Liabilities run 480.07x equity — a highly leveraged balance sheet worth noting